Mr. Chris Dallin reports

ASEP MEDICAL HOLDINGS INC. APPOINTS DR. RICHARD HEINZL AS INTERIM CEO

Asep Medical Holdings Inc.'s board member, Dr. Richard Heinzl, has been appointed interim chief executive officer and chairman of the board, succeeding Dr. Robert E.W. Hancock, as the company continues its active search for a permanent CEO.

Dr. Heinzl is a globally respected physician, humanitarian, entrepreneur and author with extensive leadership experience in health care innovation. He has been an Asep board member since Oct. 4, 2022. He founded the Canadian chapter of Medecins Sans Frontieres/Doctors Without Borders and has led health care initiatives worldwide.

Most recently, Dr. Heinzl has served as chief executive officer of My Next Health Inc., a genomics- and AI-driven (artificial intelligence) health care company, and has held senior medical leadership roles, including global medical director for WorldCare Inc., a Harvard-affiliated virtual medicine provider. He holds degrees from McMaster University, Harvard University and the University of Oxford, and has been recognized with prestigious awards, including the Harvard T.H. Chan School of Public Health Alumni Award of Merit and designation as one of the Hundred People Who Make a Difference in Canada.

"I am honoured to take on the role of interim CEO at this pivotal moment for Asep," said Dr. Heinzl. "The company's mission to develop innovative solutions for critical unmet medical needs has never been more important. I look forward to working with the team, board and partners as we execute on our strategic priorities and advance towards next-generation diagnostics and therapies."

The company also confirmed that its board and executive team are undertaking a comprehensive search for a new permanent chief executive officer.

About Asep Medical Holdings Inc.

Asep Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.